Gibson Christopher
SEC CIK 1856369 · EDGAR
BoughtSold
Most active insiders at RXRX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Borgeson Blake | Dir | — | $4.10M |
| 2 | Gibson Christopher | Dir | — | $3.84M |
| 3 | Khan Najat | Chief R, D Commercial Off, Dir | — | $806.7K |
| 4 | Taylor Ben R | CFO | — | $157.7K |
| 5 | Bumpus Namandje | Dir | — | $28.1K |
| 6 | Michor Franziska | Dir | — | — |
| 7 | Hallett David | CSO | — | — |
| 8 | Dar Zavain | Dir | — | — |
| 9 | Li Dean Y | Dir | — | — |
| 10 | Sun Elaine D | Dir | — | — |
Transactions 305
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-12-02 | 2022-12-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 601.3K | +3% | $0 |
| DMI | 2022-12-02 | 2022-12-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 500 | New | $0 |
| DMI | 2022-12-02 | 2022-12-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.28 | -2,500 | 0 | -100% | -$23.2K |
| 2022-11-17 | 2022-11-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $11.86 | -5,751 | 570.3K | -1.0% | -$68.2K | |
| DMI | 2022-11-04 | 2022-11-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $10.10 | -2,500 | 0 | -100% | -$25.3K |
| DMI | 2022-11-04 | 2022-11-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| DM | 2022-11-04 | 2022-11-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $10.00 | -36.7K | 576.0K | -6% | -$367.0K |
| D | 2022-11-04 | 2022-11-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 594.5K | +3% | $0 |
| D | 2022-11-04 | 2022-11-03 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 594.2K | +6% | +$77.5K |
| D | 2022-10-07 | 2022-10-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 580.5K | +6% | +$77.5K |
| DMI | 2022-10-07 | 2022-10-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $11.64 | -2,500 | 0 | -100% | -$29.1K |
| DMI | 2022-10-07 | 2022-10-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 500 | New | $0 |
| DM | 2022-10-07 | 2022-10-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $11.58 | -36.1K | 563.0K | -6% | -$417.4K |
| D | 2022-10-07 | 2022-10-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 581.5K | +3% | $0 |
| DM | 2022-09-02 | 2022-09-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $10.34 | -36.6K | 549.3K | -6% | -$378.0K |
| D | 2022-09-02 | 2022-09-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 567.3K | +6% | +$77.5K |
| DMI | 2022-09-02 | 2022-09-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $10.50 | -2,500 | 0 | -100% | -$26.2K |
| DMI | 2022-09-02 | 2022-09-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| D | 2022-09-02 | 2022-09-01 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 567.8K | +3% | $0 |
| 2022-08-17 | 2022-08-15 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $12.96 | -5,751 | 536.1K | -1% | -$74.5K | |
| DMI | 2022-08-05 | 2022-08-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 500 | New | $0 |
| DMI | 2022-08-05 | 2022-08-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.45 | -2,500 | 0 | -100% | -$23.6K |
| DM | 2022-08-05 | 2022-08-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.49 | -36.8K | 541.8K | -6% | -$349.5K |
| D | 2022-08-05 | 2022-08-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 560.3K | +3% | $0 |
| D | 2022-08-05 | 2022-08-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 560.2K | +6% | +$77.5K |
| D | 2022-07-08 | 2022-07-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 547.5K | +6% | +$77.5K |
| DM | 2022-07-08 | 2022-07-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.05 | -37.1K | 528.9K | -7% | -$336.1K |
| D | 2022-07-08 | 2022-07-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 547.4K | +3% | $0 |
| DMI | 2022-07-08 | 2022-07-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.07 | -2,500 | 0 | -100% | -$22.7K |
| DMI | 2022-07-08 | 2022-07-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 500 | New | $0 |
| DMI | 2022-06-06 | 2022-06-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| D | 2022-06-06 | 2022-06-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 537.5K | +6% | +$77.5K |
| DM | 2022-06-06 | 2022-06-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.09 | -39.7K | 516.3K | -7% | -$241.7K |
| D | 2022-06-06 | 2022-06-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 534.8K | +4% | $0 |
| DMI | 2022-06-06 | 2022-06-02 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.34 | -2,500 | 0 | -100% | -$15.9K |
| 2022-05-18 | 2022-05-16 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $5.67 | -5,764 | 506.2K | -1% | -$32.7K | |
| DMI | 2022-05-06 | 2022-05-04+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +5,000 | 1,000 | New | $0 |
| DMI | 2022-05-06 | 2022-05-04+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.46 | -5,000 | 0 | -100% | -$32.3K |
| DM | 2022-05-06 | 2022-05-04+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.47 | -50.3K | 512.0K | -9% | -$325.7K |
| DM | 2022-05-06 | 2022-05-04+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +37.0K | 530.5K | +7% | $0 |
| D | 2022-05-06 | 2022-05-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 525.3K | +6% | +$77.5K |
| DM | 2022-05-02 | 2022-04-28+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.14 | -75.7K | 494.1K | -13% | -$464.4K |
| DM | 2022-05-02 | 2022-04-28+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +88.0K | 488.7K | +22% | +$218.3K |
| DMI | 2022-05-02 | 2022-04-28+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.19 | -5,000 | 0 | -100% | -$30.9K |
| DMI | 2022-05-02 | 2022-04-28+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +5,000 | 1,000 | New | $0 |
| DM | 2022-05-02 | 2022-04-28+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +37.0K | 512.6K | +8% | $0 |
| DM | 2022-04-25 | 2022-04-21+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +49.0K | 438.6K | +13% | $0 |
| DM | 2022-04-25 | 2022-04-21+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.17 | -75.1K | 420.1K | -15% | -$463.7K |
| D | 2022-04-25 | 2022-04-25 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -12.0K | 444.7K | -3% | $0 |
| DMI | 2022-04-25 | 2022-04-21+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +5,000 | 500 | New | $0 |
| DMI | 2022-04-25 | 2022-04-21+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.09 | -5,000 | 0 | -100% | -$30.5K |
| DM | 2022-04-25 | 2022-04-21+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +88.0K | 438.8K | +25% | +$218.3K |
| D | 2022-04-20 | 2022-04-18 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 413.3K | +5% | $0 |
| DM | 2022-04-20 | 2022-04-18 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.84 | -35.8K | 394.8K | -8% | -$245.1K |
| DMI | 2022-04-20 | 2022-04-18 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| DMI | 2022-04-20 | 2022-04-18 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.71 | -2,500 | 0 | -100% | -$16.8K |
| D | 2022-04-20 | 2022-04-18 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +44.0K | 412.1K | +12% | +$109.1K |
| DMI | 2022-04-18 | 2022-04-14 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $7.51 | -2,500 | 0 | -100% | -$18.8K |
| DM | 2022-04-18 | 2022-04-14 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $7.56 | -34.5K | 368.1K | -9% | -$261.0K |
| DMI | 2022-04-18 | 2022-04-14 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 500 | New | $0 |
| D | 2022-04-18 | 2022-04-14 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +44.0K | 384.1K | +13% | +$109.1K |
| D | 2022-04-18 | 2022-04-14 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 386.6K | +5% | $0 |
| DMI | 2022-04-12 | 2022-04-08 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| DMI | 2022-04-12 | 2022-04-08 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.71 | -2,500 | 0 | -100% | -$16.8K |
| DM | 2022-04-12 | 2022-04-08 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.59 | -36.9K | 340.1K | -10% | -$243.1K |
| D | 2022-04-12 | 2022-04-08 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 358.5K | +5% | $0 |
| D | 2022-04-12 | 2022-04-08 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +44.0K | 358.5K | +14% | +$109.1K |
| DMI | 2022-04-11 | 2022-04-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.51 | -2,500 | 0 | -100% | -$16.3K |
| DMI | 2022-04-11 | 2022-04-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 500 | New | $0 |
| DM | 2022-04-11 | 2022-04-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.54 | -36.7K | 314.5K | -10% | -$240.3K |
| D | 2022-04-11 | 2022-04-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +44.0K | 332.8K | +15% | +$109.1K |
| D | 2022-04-11 | 2022-04-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 333.0K | +6% | $0 |
| DMI | 2022-04-08 | 2022-04-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| D | 2022-04-08 | 2022-04-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +44.0K | 306.1K | +17% | +$109.1K |
| DMI | 2022-04-08 | 2022-04-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.56 | -2,500 | 0 | -100% | -$16.4K |
| D | 2022-04-08 | 2022-04-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 307.2K | +6% | $0 |
| DM | 2022-04-08 | 2022-04-06 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.77 | -35.8K | 288.7K | -11% | -$242.6K |
| DMI | 2022-04-07 | 2022-04-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| DM | 2022-04-07 | 2022-04-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $7.44 | -34.5K | 262.1K | -12% | -$256.3K |
| DMI | 2022-04-07 | 2022-04-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $7.31 | -2,500 | 0 | -100% | -$18.3K |
| D | 2022-04-07 | 2022-04-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 280.6K | +7% | $0 |
| D | 2022-04-07 | 2022-04-05 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +44.0K | 278.0K | +19% | +$109.1K |
| DM | 2022-03-15 | 2022-03-11+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +336.1K | 464.0K | +263% | $0 |
| DM | 2022-03-15 | 2022-03-11+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $6.48 | -336.1K | 234.0K | -59% | -$2.18M |
| D | 2022-03-09 | 2022-03-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $7.30 | -300.0K | 234.0K | -56% | -$2.19M |
| D | 2022-03-09 | 2022-03-07 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +300.0K | 534.0K | +128% | $0 |
| D | 2022-02-24 | 2022-02-22 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +100.0K | 334.0K | +43% | $0 |
| D | 2022-02-24 | 2022-02-22 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $10.22 | -100.0K | 234.0K | -30% | -$1.02M |
| DM | 2022-02-08 | 2022-02-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | A - Grant | $0.00 | +210.9K | 234.4K | +899% | $0 |
| D | 2022-02-08 | 2022-02-04 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | F - Tax | $11.40 | -343 | 234.0K | -0.1% | -$3,910 |
| D | 2022-02-02 | 2022-01-31 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +19.9K | 43.3K | +85% | $0 |
| D | 2022-02-02 | 2022-01-31 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $11.73 | -19.9K | 23.5K | -46% | -$232.9K |
| DM | 2022-01-14 | 2022-01-13+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +341.0K | 277.5K | New | $0 |
| DM | 2022-01-14 | 2022-01-13+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $13.76 | -341.0K | 23.5K | -94% | -$4.69M |
| D | 2021-12-20 | 2021-12-16 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +200 | 23.7K | +0.9% | $0 |
| D | 2021-12-20 | 2021-12-16 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $20.01 | -200 | 23.5K | -0.8% | -$4,002 |
| D | 2021-12-15 | 2021-12-13 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +100 | 23.6K | +0.4% | $0 |
| D | 2021-12-15 | 2021-12-13 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale | $20.02 | -100 | 23.5K | -0.4% | -$2,002 |
| DM | 2021-12-10 | 2021-12-08+ | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | S - Sale+OE | $20.14 | -11.8K | 23.5K | -33% | -$236.6K |
| D | 2021-12-10 | 2021-12-08 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | CEO, Dir | M - OptEx | $2.47 | +28.6K | 28.6K | New | +$70.8K |
Purchase Sale Sale after option exercise All abbreviations